Detailed Role of Mesenchymal Stem Cell (Msc)-Derived Exosome Therapy in Cardiac Diseases Publisher



Hassanzadeh A¹ ; Shomali N^{2, 3} ; Kamrani A^{2, 3} ; Nasiri H³ ; Heris JA⁴ ; Pashaiasl M^{5, 6} ; Sadeghi M⁷ ; Sadeghvand S⁸ ; Valedkarimi Z³ ; Akbari M^{3, 9} Show Affiliations
Source: EXCLI Journal Published:2024

Abstract

Coronary heart disease (CHD) continues to be the leading cause of morbidity and mortality. There are numerous therapeutic reperfusion methods, including thrombolytic therapy, primary percutaneous coronary intervention, and anti-remodeling drugs like angiotensin-converting enzyme inhibitors and beta-blockers. Despite this, there is no pharmacological treatment that can effectively stop cardiomyocyte death brought on by myocardial ischemia/reperfusion (I/R) injury. For the purpose of regenerating cardiac tissue, mesenchymal stem cell (MSC) therapy has recently gained more attention. The pleiotropic effects of MSCs are instead arbitrated by the secretion of soluble paracrine factors and are unrelated to their capacity for differentiation. One of these paracrine mediators is the extracellular vesicle known as an exosome. Exosomes deliver useful cargo to recipient cells from MSCs, including peptides, proteins, cytokines, lipids, miRNA, and mRNA molecules. Exosomes take part in intercellular communication processes and help tissues and organs that have been injured or are ill heal. Exosomes alone were found to be the cause of MSCs' therapeutic effects in a variety of animal models, according to studies. Here, we have focused on the recent development in the therapeutic capabilities of exosomal MSCs in cardiac diseases. © 2024, Leibniz Research Centre for Working Environment and Human Factors. All rights reserved.